Amyloidosis occurs when an abnormal protein known as amyloid accumulates in tissues and organs, altering their structure and function, posing a serious threat to health and potentially leading to organ failure.
Table of Contents
Causes and Varieties of Amyloidosis
Numerous proteins can contribute to the formation of amyloid deposits, but only a subset are associated with significant health complications. The specific protein involved and its site of accumulation determine the subtype of amyloidosis. Amyloid deposits can manifest systemically or locally within the body.
The various forms of amyloidosis encompass:
AL amyloidosis (immunoglobulin light chain amyloidosis), formerly labeled primary amyloidosis. AL denotes “amyloid light chains,” the protein type responsible for this condition. Its origin remains unknown, but it typically arises from abnormal antibody production by the bone marrow, often associated with multiple myeloma, impacting organs such as the kidneys, heart, liver, intestines, and nerves.
AA amyloidosis, previously termed secondary amyloidosis, arises as a consequence of chronic inflammatory or infectious diseases like rheumatoid arthritis, Crohn’s disease, or ulcerative colitis. Predominantly affecting the kidneys, it can also involve the digestive tract, liver, and heart, with amyloid type A protein being the causative agent.
Dialysis-related amyloidosis (DRA) is more prevalent in older individuals and those undergoing dialysis for extended periods, characterized by the accumulation of beta-2 microglobulin in the bloodstream. While deposits may occur in various tissues, they commonly affect bones, joints, and tendons.
Familial or hereditary amyloidosis, a rare inherited form, typically impacts the liver, nerves, heart, and kidneys, with several genetic anomalies predisposing individuals to the condition, often involving abnormal proteins like transthyretin (TTR).
Age-related (senile) systemic amyloidosis results from the deposition of normal TTR primarily in the heart and other tissues, predominantly observed in older males.
Organ-specific amyloidosis leads to amyloid protein deposition in specific organs, such as the skin (cutaneous amyloidosis).
While certain amyloid deposits have been associated with Alzheimer’s disease, systemic amyloidosis rarely affects the brain despite its systemic nature.
Risk Factors Associated with Amyloidosis
Amyloidosis occurs more frequently in men compared to women, and the likelihood of developing it increases with age. Approximately 15% of individuals diagnosed with multiple myeloma, a type of cancer, also experience amyloidosis.
Furthermore, amyloidosis may manifest in individuals with end-stage kidney disease who undergo prolonged dialysis treatment, a condition referred to as “Dialysis-related amyloidosis.”
Symptoms of Amyloidosis
The symptoms of amyloidosis tend to be subtle and can vary depending on the location of amyloid protein accumulation within the body. It’s important to recognize that the symptoms outlined below could be indicative of various health issues. A definitive diagnosis of amyloidosis can only be made by a healthcare professional.
Common symptoms of amyloidosis may include:
Changes in skin pigmentation
Persistent fatigue
Sense of abdominal fullness
Joint discomfort
Decreased red blood cell count (anemia)
Breathing difficulties
Tongue swelling
Numbness and tingling sensations in the legs and feet
Weakness in grip strength
Severe muscle weakness
Unexplained weight loss
Cardiac Amyloidosis (Stiff Heart Syndrome)
Cardiac Amyloidosis, also known as “Stiff Heart Syndrome,” can result in reduced blood flow to the heart muscle, leading to eventual impairment of normal pumping function. Some medical professionals consider “stiff heart syndrome” to be a symptom of cardiac amyloidosis, while others use it interchangeably to describe the condition. In either case, the accumulation of amyloid deposits in the heart can cause stiffening of the cardiac walls, weaken the heart muscle, and disrupt its electrical rhythm. This syndrome can pose serious risks, potentially progressing to congestive heart failure if left untreated.
The demographic at higher risk for cardiac amyloidosis comprises predominantly men and older individuals, with the condition rarely affecting those under 40. Inheritance plays a role in predisposing individuals to stiff heart syndrome, along with factors such as untreated hypertension, obesity, advanced age, and menopause.
Symptoms of cardiac amyloidosis affecting the heart may manifest as shortness of breath during mild physical exertion or while lying down, irregular heartbeat, and indications of heart failure, including swelling in the lower extremities, weakness, fatigue, and nausea.
Diagnosis typically involves a thorough evaluation of symptoms, family history, and physical examination, alongside various tests such as blood and urine analyses, imaging studies (e.g., ultrasound, echocardiogram, electrocardiogram, MRI, CT scan), biopsy, and genetic testing if there’s a familial predisposition.
Treatment approaches for cardiac amyloidosis vary depending on the specific type diagnosed. Options may include medications such as chemotherapy and immunotherapy, placement of a pacemaker, or a stem cell transplant. While some treatments overlap with those used for cancer, it’s important to note that cardiac amyloidosis is a distinct condition affecting the heart muscle, albeit without a cure. Early diagnosis is crucial as it enables timely intervention to mitigate permanent damage and manage the condition effectively.
Renal (Kidney) Amyloidosis
Renal Amyloidosis affects the kidneys, hindering their ability to filter waste and toxins from the blood. This can lead to water and toxin accumulation in the body, manifesting symptoms such as:
– Swelling of the feet and ankles, and puffiness around the eyes, indicating kidney failure
– Elevated protein levels in urine
Gastrointestinal Amyloidosis
Gastrointestinal Amyloidosis impacts the GI tract, slowing down food movement through the intestines and causing digestive issues, including:
– Decreased appetite
– Diarrhea
– Nausea
– Stomach pain
– Weight loss
Liver involvement in amyloidosis can result in liver enlargement and fluid retention in the body.
Amyloid Neuropathy
Amyloid Neuropathy damages peripheral nerves, responsible for transmitting information between the brain, spinal cord, and the body, leading to:
– Balance issues
– Bladder and bowel control problems
– Sweating abnormalities
– Tingling sensations and weakness
– Dizziness upon standing due to blood pressure regulation issues
Amyloidosis Diagnosis
Accurate diagnosis of amyloidosis relies on a thorough physical examination and a comprehensive review of your medical history, both of which are crucial for your doctor to pinpoint the condition.
Blood and urine analyses are capable of detecting abnormal proteins, while additional assessments, such as thyroid and liver evaluations, may be conducted depending on your symptoms.
Confirmation of an amyloidosis diagnosis typically involves a biopsy, allowing your doctor to identify the specific type of protein present. Biopsy samples may be obtained from various locations, including abdominal fat, bone marrow, mouth, rectum, or other affected organs, although biopsy of the affected area is not always necessary.
Imaging tests are also utilized to gauge organ damage, particularly to vital organs like the heart, liver, or spleen.
In cases where hereditary amyloidosis is suspected, genetic testing may be recommended, as the treatment approach differs from other forms of the condition.
Following diagnosis, additional assessments, such as echocardiograms or imaging scans of the liver and spleen, may be performed by your doctor.
Management of Amyloidosis
While amyloidosis cannot be cured, treatment focuses on slowing the progression of amyloid protein accumulation and alleviating symptoms. Treatment plans may vary depending on the specific type of amyloidosis and the extent of organ involvement.
For primary AL amyloidosis, high-dose chemotherapy coupled with stem cell transplant may be utilized to target the underlying cause. In some cases, chemotherapy alone is employed.
Secondary (AA) amyloidosis is managed by addressing the underlying disorder and administering potent anti-inflammatory medications, such as steroids.
Certain types of hereditary amyloidosis may necessitate a liver transplant.
Emerging therapies aimed at reducing abnormal protein production, particularly TTR, show promise.
Additional symptomatic treatments may include diuretics to manage fluid retention, thickeners to prevent swallowing difficulties, compression stockings for leg or feet swelling, and dietary adjustments, particularly for gastrointestinal amyloidosis.